Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer

Abstract

This study demonstrates that, despite a significant progression-free survival advantage, the addition of bevacizumab to paclitaxel is not cost effective for the cohort of patients with HER2-negative MBC included in our analysis. Such data could be informative to policymakers who consider the health economics and incremental cost-effectiveness of medical therapies.